Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma

Clinical Cancer Research

Volumn 13, Issue 2 I, 2007, Pages 475-481

  Hillengass, Jens ^a   Wasser, Klaus ^e   Delorme, Stefan ^b   Kiessling, Fabian ^b   Zechmann, Christian ^b   Benner, Axel ^c   Kauczor, Hans Ulrich ^b   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a,d   Moehler, Thomas M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Radiology ^*  (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d National Center of Tumor Diseases   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE;

ADULT; AGE; ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER RELAPSE; CANCER SURVIVAL; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; BONE MARROW CELLS; CONTRAST MEDIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846880054     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0061     Document Type: Article

References (37)

1. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565-9.
2. Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001;80:695-705.
3. Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 1995;20:27-38.
4. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
5. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004;10:1221-34.
6. Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma. Blood Rev 2002;16:207-15.
7. Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park, NY) 2000;14:S11-6.
8. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995;33:506-14.
9. Hawighorst H, Weikel W, Knapstein PG, et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998;4:2305-12.
10. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-6.
11. Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003;13:80-7.
12. Hawighorst H, Knopp MV, Debus J, et al. Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging 1998;8:783-8.
13. Rahmouni A, Divine M, Mathieu D, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993;160:1053-7.
14. Moehler TM, Hawighorst H, Neben K, et al. Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 2001;93:862-8.
15. Rahmouni A, Divine M, Mathieu D, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol 1993;160:1049-52.
16. Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H, Knopp MV. Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography. Radiologe 1997;37:470-80.
17. Nosas-Garcia S, Moehler T, Wasser K, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 2005;22:154-62.
18. Scherer A, Wittsack HJ, Strupp C, Gattermann N, Haas R, Modder U. Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging. Ann Hematol 2002;81:517-21.
19. Wasser K, Moehler T, Neben K, et al. Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy. RoFo 2004;176:1285-95.
20. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002;8:3377-82.
21. Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001;98:3846-8.
22. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-8.
23. Baur A, Stabler A, Steinborn M, et al. Magnetic resonance tomography in plasmacytoma: ranking of various sequences in diffuse and focal infiltration patterns. RoFo 1998;168:323-9.
24. Stabler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996;167:1029-36.
25. Rahmouni A, Montazel JL, Divine M, et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003;229:710-7.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
27. Lawless JF, Singhal K. Efficient screening of nonnormal regression models. Biometrics 1978;34:318-27.
28. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
29. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
30. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005;128:210-7.
31. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005;55:56-63.
32. Baur A, Stabler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-45.
33. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 1994;2:633-58.
34. Ercolani P, Valeri G, Amici F. Dynamic MRI of the breast. Eur J Radiol 1998;27 Suppl 2:S265-71.
35. Stack JP, Redmond OM, Codd MB, Dervan PA, Ennis JT. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990;174:491-4.
36. Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52:420-9.
37. Furman-Haran E, Kelcz F, Degani H. Magnetic resonance imaging of breast cancer angiogenesis: a review. J Exp Clin Cancer Res 2002;21:47-54.